Vor Biopharma (NYSE:VOR) Given Outperform Rating at Oppenheimer

Oppenheimer reiterated their outperform rating on shares of Vor Biopharma (NYSE:VOR) in a research report released on Friday morning,Benzinga reports. The firm currently has a $8.00 price objective on the stock.

A number of other equities research analysts have also issued reports on VOR. Wedbush reaffirmed an “outperform” rating and set a $7.00 target price on shares of Vor Biopharma in a research report on Thursday. Stifel Nicolaus cut their target price on Vor Biopharma from $12.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday. JMP Securities reaffirmed a “market outperform” rating and set a $12.00 target price on shares of Vor Biopharma in a research report on Tuesday, December 10th. Finally, HC Wainwright cut their target price on Vor Biopharma from $17.50 to $13.00 and set a “buy” rating on the stock in a research report on Friday. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $8.86.

Vor Biopharma Stock Up 2.1 %

Shares of Vor Biopharma stock opened at $0.87 on Friday. The firm has a market cap of $59.75 million, a price-to-earnings ratio of -0.53 and a beta of -0.40. The business has a fifty day simple moving average of $1.22 and a 200-day simple moving average of $1.01. Vor Biopharma has a fifty-two week low of $0.63 and a fifty-two week high of $2.43.

Institutional Trading of Vor Biopharma

Several hedge funds have recently added to or reduced their stakes in VOR. RA Capital Management L.P. boosted its stake in Vor Biopharma by 74.3% during the 4th quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company’s stock valued at $44,007,000 after purchasing an additional 16,897,159 shares during the period. Lynx1 Capital Management LP bought a new stake in Vor Biopharma during the 4th quarter valued at approximately $707,000. Trustees of Columbia University in the City of New York bought a new stake in Vor Biopharma during the 4th quarter valued at approximately $102,000. XTX Topco Ltd bought a new stake in Vor Biopharma during the 4th quarter valued at approximately $80,000. Finally, Virtu Financial LLC acquired a new position in Vor Biopharma in the 4th quarter valued at approximately $60,000. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.